reports
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Guy Sips
Agfa FIRST LOOK: Weak Radiology Solutions and strong HealthCare IT in ...
1Q25 was marked by a weak performance in Radiology Solutions (1Q is traditionally a seasonally weak quarter but now with strong impact of the decline of the medical film markets, particularly in China) and the continued strong performance of Agfa's HealthCare IT division, driven by customer adoption of Agfa's cloud technology. While Agfa's Digital Printing Solutions equipment business faced challenges due to economic uncertainty, and the market for Agfa's Zirfon membranes for green hydrogen prod...
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 20...
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Regulated information May 14, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Group performance: continued success of the strategic transformation Improved sales mix between growth engines and mature businesses and good cost control compensated for the negative impact of the market ...
De Agfa-Gevaert Groep in het eerste kwartaal van 2025: aangepaste EBIT...
De Agfa-Gevaert Groep in het eerste kwartaal van 2025: aangepaste EBITDA stabiel tegenover eerste kwartaal van 2024 – verbeterde mix en goede kostcontrole compenseerde voor de achteruitgang van de filmmarkt Gereglementeerde informatie 14 mei 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het eerste kwartaal van 2025: aangepaste EBITDA stabiel tegenover eerste kwartaal van 2024 – verbeterde mix en goede kostcontrole compenseerde voor de achteruitgang van de filmmarkt Groepsprestatie: voortgezet succes van de strategische t...
Annual General Meeting of Agfa-Gevaert NV - regulated information
Annual General Meeting of Agfa-Gevaert NV - regulated information May 13, 2025 – 5.40 PM CET Regulated information Annual General Meeting of Agfa-Gevaert NV Mortsel, Belgium – May 13, 2025 – 5.40 p.m. CET At Agfa-Gevaert's Annual General Meeting, the 2024 financial statements, the allocation of the result, the remuneration report, the remuneration policy and the discharge of directors and statutory auditor were approved. Furthermore, the shareholders rendered available all share premiums that can be rendered available without specific formaliti...
Jaarlijkse Algemene Aandeelhouders-vergadering van Agfa-Gevaert NV - g...
Jaarlijkse Algemene Aandeelhouders-vergadering van Agfa-Gevaert NV - gereglementeerde informatie 13 mei 2025 – 17u40 CET Gereglementeerde informatie Jaarlijkse Algemene Aandeelhouders-vergadering van Agfa-Gevaert NV Mortsel, België – 13 mei 2025 – 17u40 CET Op de Jaarlijkse Algemene Aandeelhoudersvergadering van Agfa-Gevaert werden de jaarrekening van het boekjaar 2024, de bestemming van het resultaat, het remuneratieverslag en het remuneratiebeleid goedgekeurd. Tevens werd er kwijting verleend aan de bestuurders en de commissaris. Voorts stelden de aandeelhouders alle uitgiftepremies...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), May 13, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total a...
Zealand Pharma to participate in upcoming healthcare investor conferen...
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following healthcare investor conferences in May and June 2025: Bank of America Global Healthcare Conference, May 13-15 in L...
Zealand Pharma announces closing of collaboration and license agreemen...
Zealand Pharma announces closing of collaboration and license agreement with Roche Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche have been satisfied, including regulatory conditions, and the ag...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Uneventful 1Q25 results, dapi phase 1 higher dose data ...
Zealand reported uneventful 1Q25 results with a cash position of DKK 8,545m to be supplemented with a $1.4b (approx. DKK 9.24b) upfront from Roche in 2Q25. Pipeline timelines were reiterated, and while the later stage datasets are expected in 1H26, we look forward to results from the higher dose cohort from the phase 1b trial of dapiglutide (GLP-1/GLP-2 analog) in overweight/obese patients in 2Q25. In addition, we expect read-through from cagrisema's (GLP-1/amylin analog) full dataset potentiall...
Zealand Pharma Announces Financial Results for the First Three Months ...
Zealand Pharma Announces Financial Results for the First Three Months of 2025 Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to...
dsm-firmenich shareholders approve all resolutions at Annual General M...
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025 Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announces that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting today, including the Management Report, the consolidated financial statements as well as the Sustainability Report 2024. Key highlights include: Thomas Leysen was re-elected...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total am...
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present...
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the ...
- Ahmed Ben Salem
DHL DHL GROUP
FP TOTAL SE
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
KNEBV KONE OYJ CLASS B
TKA TELEKOM AUSTRIA AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
MMK MAYR-MELNHOF KARTON AG
OMV OMV AG
AMUN AMUNDI SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
REP REPSOL SA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
KGX KION GROUP AG
AENA AENA SME SA
ANDR ANDRITZ AG
SNP PETROM S.A.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
ADYEN ADYEN NV
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
GSK GSK PLC
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
- Ahmed Ben Salem
DHL DHL GROUP
FP TOTAL SE
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
KNEBV KONE OYJ CLASS B
TKA TELEKOM AUSTRIA AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
MMK MAYR-MELNHOF KARTON AG
OMV OMV AG
AMUN AMUNDI SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
REP REPSOL SA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
AENA AENA SME SA
ANDR ANDRITZ AG
SNP PETROM S.A.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
ADYEN ADYEN NV
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
GSK GSK PLC
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
- Stefano Toffano
- ING Helpdesk
Benelux Morning Notes
Aedifica: Strong Q1, improving fundamentals, further growth to come. Air France-KLM: Surprising Atlantic. Aperam: In-line 1Q25, seasonal better 2Q25 expected. ArcelorMittal: In-line 1Q25, risks to steel demand due to tariff uncertainty. ASM International: 1Q25 Results - FY25 headwinds from weak USD. Ayvens: Getting into Gear. dsm-firmenich: Transformation on Track. Lotus Bakeries: Peer Mondelez 1Q25 results. Melexis: Mixed 1Q25 results in unstable markets. Ontex: Two steps fo...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.